Caries Vaccine (Anti-Caries Vaccination)

What Is It?

Why S. mutans?

Target Antigens for Vaccine Development

1. Protein Antigen c (PAc / Antigen I/II)

• A surface fibrillar adhesin critical for sucrose-independent attachment to tooth surfaces
• Most extensively studied antigen
• Mucosal immunization with PAc-based vaccines consistently raises salivary secretory IgA (sIgA), which blocks bacterial adherence

2. Glucosyltransferases (GTFs)

• Catalyze production of sticky glucan polymers from sucrose, enabling biofilm formation
• GTF-I, GTF-SI (encoded by gtfB, gtfC, gtfD genes)
• Purified GTF protein tested in monkey models - showed modest IgA response but did not clearly reduce colonization by itself
• DNA vaccines encoding GTFs show better immunogenicity

3. Glucan-binding Proteins (GBPs)

• GbpA, GbpB, GbpC - anchor the biofilm matrix
• GbpB is the most immunogenic and is a promising subunit vaccine candidate
• GlnH (glutamate binding protein) - a recently identified mucosal vaccine candidate (de Souza Pereira et al., 2022)

Types of Vaccines Under Investigation

1. Whole-Cell Vaccines

• Made from killed/formalin-treated S. mutans (e.g., KFD2-rPAc)
• Early studies; concerns about cross-reactivity with cardiac tissue (molecular mimicry)
• Safety profile still debated, though cross-reactivity is low

2. Subunit / Protein Vaccines

• Purified proteins (PAc, GBPs, GTFs) or recombinant fragments
• KFD2-rPAc (killed formalin-treated donor strain 2 + recombinant PAc): demonstrated sustained reduction in S. mutans colonization

3. DNA Vaccines

• Plasmids encoding S. mutans antigens (e.g., GTFs, PAc)
• Induce both humoral and cell-mediated immunity
• Most current preclinical work uses DNA vaccine platforms
• Co-immunization with cytokine/chemokine adjuvants (e.g., IL-2, GM-CSF genes) enhances response

4. Passive Immunization / Monoclonal Antibodies

• CaroRx (Guy's 13 antibody, SecretA): Plantibody produced in transgenic tobacco plants by Planet Biotechnology; applied topically to teeth every few months to prevent S. mutans recolonization - Phase II clinical trials were discontinued in 2016
• Anti-CAT-SYIIgY antibodies (egg yolk IgY): showed prophylactic effects against colonization

5. Nanoparticle-Based Vaccines

• ZIF-8@PAc (PAc loaded in zeolitic imidazolate framework nanoparticles): shown to elicit stronger and more persistent IgG and sIgA responses in rat models compared to alum adjuvant alone, with no systemic toxicity (ASM Spectrum, 2023)

6. Replacement Therapy (Biological Approach)

• Oragenics BCS3-L1: A genetically modified S. mutans strain with the lactate dehydrogenase gene deleted - produces no lactic acid. Idea: colonize the mouth with this harmless strain to outcompete wild-type S. mutans
• FDA Phase I trial (2004-2006): enrolled only 10 subjects; development shelved in 2014 due to regulatory/patent issues
• Lantern Bioworks "Lumina": A similar next-generation replacement strategy; currently offered commercially via direct-to-consumer channels outside mainstream clinical trial frameworks (as of 2024-2025)

7. Multiepitope Vaccines (MEV) - Computational/Immunoinformatics

• In silico design combining B-cell and T-cell epitopes from multiple S. mutans virulence proteins
• Promising preclinical immunogenicity modeling but no human trials yet (Naorem et al., 2024)

Route of Immunization

Immune Response Sought

• Effective vaccines produce a combined Th1, Th2, and Th17 immune response
• Th1 suppression is favorable in terms of reducing inflammatory tissue damage
• ERK/MAPK, NF-kB, and inflammasome signaling pathways are implicated
• Multivalent vaccines that inhibit SOCS (suppressors of cytokine signaling) genes are proposed as the next-generation target
• Both salivary sIgA (prevents colonization) and serum IgG (systemic) responses are needed

Key Clinical / Animal Evidence

• Pooled RR = 0.53 (95% CI: 0.46-0.62) - a statistically significant 47% reduction in risk across studies
• Vaccines like KFD2-rPAc and anti-CAT-SYIIgY IgY demonstrated prophylactic effects against S. mutans colonization
• Conclusion: "Excellent potential for dental caries vaccines to transform oral health in the future"

Challenges and Limitations

1. Molecular mimicry concern: S. mutans antigens (particularly GTFs) share epitopes with human cardiac tissue - risk of autoimmune cross-reaction, though this is considered low in practice
2. Durability: Salivary IgA has a short half-life; long-lasting protection is hard to achieve
3. Complex oral microbiome: Disrupting S. mutans may alter the broader oral ecosystem unpredictably
4. Route of delivery: Achieving effective mucosal immunity without systemic adjuvant toxicity remains difficult
5. Enrollment challenges: Strict FDA criteria hampered earlier human trials (e.g., Oragenics required edentulous patients under 55)
6. No Phase III human RCT completed to date

Current Status (as of 2025-2026)

• No approved caries vaccine exists anywhere in the world
• Most candidates remain in preclinical (animal) or early Phase I/II stages
• The field has shifted toward nanoparticle delivery, DNA platforms, multiepitope designs, and mucosal adjuvants
• The 2025 meta-analysis confirms the concept is scientifically valid; human efficacy trials are urgently needed
• Commercial "replacement" approaches (e.g., Lumina) operate outside mainstream vaccine regulatory frameworks

Summary Table of Vaccine Types